Menopause hormone therapy significantly alters pathophysiological biomarkers of Alzheimer's disease
Résumé
Introduction: This increasing body of literature indicates that menopause hormonal replacement therapy (MHT) may substantially mitigate the risk of developing late-life cognitive decline due to progressive Alzheimer's disease (AD) pathophysiology. For the first time, we investigated the question whether MHT impacts AD biomarker-informed pathophysiological dynamics in de-novo diagnosed menopausal women. Methods: We analyzed baseline and longitudinal differences between MHT-taking and-not women in terms of concentrations of core pathophysiological AD plasma biomarkers, validated in symptomatic and cognitively healthy individuals, including biomarkers of (1) the amyloid-β (Aβ) pathway, (2) tau pathophysiology, (3) neuronal loss, and (4) axonal damage and neurodegeneration. Results: We report a prominent and significant treatment response at the Aβ pathway biomarker level. Women at genetic risk for AD (APOE e4 allele carriers) have particularly shown favorable results from treatment. Discussion: To our knowledge, we present first prospective clinical evidence on effects of MHT on AD pathophysiology during menopause.
Domaines
Sciences du Vivant [q-bio]
Fichier principal
ALZ & DEM_Menopause hormone therapy alters AD biomarkers_2022.pdf (632.44 Ko)
Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)